A growing emphasis on academic and nonprofit organization partnerships could rescue the pharmaceutical industry from the redundancy of an inefficient R&D model and plug the so-called ?innovation gap, according to a new report from research and consulting firm GlobalData.
GlobalData’s new report argues that collaboration in drug development benefits both parties, with academia constantly looking for sources of research funding? particularly as governments cut the amount of aid dedicated to federally funded research,?while the pharmaceutical industry would gain a partner to share in the high risks and substantial costs of bringing…
The Industry’s Research Commitment Remains Strong
Impact of Rare Diseases